within Pharmacolibrary.Drugs.ATC.R;

model R03DA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 4.6666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Theophylline is a methylxanthine drug used as a bronchodilator in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. It has been largely supplanted by newer agents but is still used clinically, particularly for patients in whom inhaled therapies are not suitable.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetics from healthy adult subjects following oral immediate-release administration.</p><h4>References</h4><ol><li><p>Reinhart, JM, et al., &amp; Li, Z (2022). Pharmacokinetics of a 503B outsourcing facility-produced theophylline in dogs. <i>PloS one</i> 17(1) e0262336–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0262336&quot;>10.1371/journal.pone.0262336</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34990472/&quot;>https://pubmed.ncbi.nlm.nih.gov/34990472</a></p></li><li><p>Cavett, CL, et al., &amp; Reinhart, JM (2019). Pharmacokinetics of a modified, compounded theophylline product in dogs. <i>Journal of veterinary pharmacology and therapeutics</i> 42(6) 593–601. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12813&quot;>10.1111/jvp.12813</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31529628/&quot;>https://pubmed.ncbi.nlm.nih.gov/31529628</a></p></li><li><p>Bolme, P, et al., &amp; Paalzow, L (1982). Pharmacokinetics and dose regimen of oral theophylline in children. <i>Acta pharmacologica et toxicologica</i> 51(5) 401–406. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1982.tb01044.x&quot;>10.1111/j.1600-0773.1982.tb01044.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7164821/&quot;>https://pubmed.ncbi.nlm.nih.gov/7164821</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DA04;
